Synairgen plc (LON:SNG – Get Free Report)’s share price shot up 33.3% during trading on Monday . The company traded as high as GBX 3 ($0.04) and last traded at GBX 3 ($0.04). 205,983 shares changed hands during trading, a decline of 38% from the average session volume of 332,641 shares. The stock had previously closed at GBX 2.25 ($0.03).
Synairgen Stock Performance
The company has a market capitalization of £6.04 million, a P/E ratio of -100.00 and a beta of -2.23. The business has a 50 day moving average of GBX 4.03 and a 200 day moving average of GBX 4.16. The company has a quick ratio of 6.35, a current ratio of 6.77 and a debt-to-equity ratio of 0.09.
About Synairgen
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease.
Read More
- Five stocks we like better than Synairgen
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Cold Front, Hot Stocks: Diesel Prices Propel Energy Leaders
- Insider Buying Explained: What Investors Need to Know
- Sustainable and Successful: 3 Climate ETFs Beating the Market
- Technology Stocks Explained: Here’s What to Know About Tech
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.
